Tedaldi E, Baker R, Moorman A, Alzola C, Tong T, Wood K, Walker-Kornegay L, Ording-Bauer L, Kelly R, Esteves J, McCabe R, Rachel M, Holmberg S; Conference on Retroviruses and Opportunistic Infections.
9th Conf Retrovir Oppor Infect Feb 24 28 2002 Wash State Conv Trade Cent Seattle Wash Conf Retrovir Oppor Infect 9th 2002 Seattle Wash. 2002 Feb 24-28; 9: abstract no. 659-M.
Temple Univ. Hosp., Philadelphia, PA
BACKGROUND: Co-infection with HIV and hepatitis C (HCV) has been reported to influence survival, antiretroviral use, and disease progression.We compared mortality rates, co-morbidities, and antiretroviral use in an observational cohort of HIV patients with and without HCV.METHODS: Study participants came from 3 HIV Outpatient Study (HOPS) sites with large numbers of HIV/HCV co-infected patients followed at least 6 months since January 1996 up to January 2001. Demographic variables; baseline and current CD4 counts; HAART use; clinical diseases and conditions, and survival were compared between HIV only and HIV/HCV co-infected patients. Bivariate and multivariate analyses were used to examine statistical differences between the HIV only and HIV/HCV co-infected patients.RESULTS: Of 852 HCV-tested HOPS patients in this analysis, 320 (37.6%) were HIV/HCV co-infected. Compared to HIV-only-infected persons, HIV/HCV co-infected patients were more likely to be older (median age, 40.8 vs 35.3 years, p< 0.0001), less educated (25.3% vs 16.9% with less than a high school education, p< 0.0001), insured by Medicaid (61.2% vs 43.0%, p< 0.0001), and have intravenous drug use as their HIV risk factor (69.4% vs 6.0%; p< 0.0001). HIV/HCV co-infected patients also had higher rates of AIDS (67.5% vs 61.1%; p= 0.06), renal disease (6.3% vs 3.0%; p= 0.02), and cardiovascular disease (24.4% vs 17.3%; p= 0.01). Deaths per 100 person-years of observation were higher in HIV/HCV co-infected patients (3.4 vs 1.7/100 person-years; p = 0.008). However, multivariate analyses adjusting for baseline CD4+ cell count and number of weeks on HAART showed no statistically significant difference in survival time between HCV/HIV co-infected and HIV only patients (p= 0.56). Baseline CD4+ cells and length of time on HAART were both significant predictors of survival.CONCLUSIONS: In a multivariate analysis correcting for baseline CD4+ cell count and HAART use, survival times between HIV patients with and without HCV co-infection were found to be comparable. HAART was the strongest predictor of survival, suggesting treatment is more important to survival than co-infection with HCV.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- CD4 Lymphocyte Count
- Communicable Diseases
- Disease Progression
- HIV
- HIV Infections
- HIV Seropositivity
- Hepacivirus
- Hepatitis C
- Hepatitis C Antibodies
- Humans
- Morbidity
- epidemiology
- mortality
- utilization
Other ID:
UI: 102263696
From Meeting Abstracts